- Home
- EDF vs VTYX Comparison
EDF vs VTYX Comparison
Compare EDF & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- VTYX
- Stock Information
- Founded
- EDF 2010
- VTYX 2018
- Country
- EDF United States
- VTYX United States
- Employees
- EDF N/A
- VTYX N/A
- Industry
- EDF Investment Managers
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- EDF Finance
- VTYX Health Care
- Exchange
- EDF Nasdaq
- VTYX Nasdaq
- Market Cap
- EDF 160.2M
- VTYX 154.9M
- IPO Year
- EDF N/A
- VTYX 2021
- Fundamental
- Price
- EDF $5.08
- VTYX $2.31
- Analyst Decision
- EDF
- VTYX Buy
- Analyst Count
- EDF 0
- VTYX 2
- Target Price
- EDF N/A
- VTYX $9.00
- AVG Volume (30 Days)
- EDF 160.6K
- VTYX 448.0K
- Earning Date
- EDF 01-01-0001
- VTYX 11-06-2025
- Dividend Yield
- EDF 13.14%
- VTYX N/A
- EPS Growth
- EDF N/A
- VTYX N/A
- EPS
- EDF N/A
- VTYX N/A
- Revenue
- EDF N/A
- VTYX N/A
- Revenue This Year
- EDF N/A
- VTYX N/A
- Revenue Next Year
- EDF N/A
- VTYX N/A
- P/E Ratio
- EDF N/A
- VTYX N/A
- Revenue Growth
- EDF N/A
- VTYX N/A
- 52 Week Low
- EDF $3.51
- VTYX $0.78
- 52 Week High
- EDF $5.50
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- EDF 45.91
- VTYX 40.73
- Support Level
- EDF $4.97
- VTYX $2.26
- Resistance Level
- EDF $5.09
- VTYX $2.51
- Average True Range (ATR)
- EDF 0.06
- VTYX 0.15
- MACD
- EDF -0.01
- VTYX -0.01
- Stochastic Oscillator
- EDF 41.30
- VTYX 14.35
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.